HUE027757T2 - Treatment of diseases associated with the use of antibiotics - Google Patents

Treatment of diseases associated with the use of antibiotics Download PDF

Info

Publication number: HUE027757T2
Authority: HU; Hungary
Prior art keywords: iks; compound; antibiotic; lake; ids
Prior art date: 2004-05-14

Application number

HUE09156339A

Other languages

English (en)

Hungarian (hu)

Inventor

Youe-Kong Shue

Farah Kondori Babakhani

Franklin W Okumu

Pamela Suzanne Sears

Starr Louise Miller-Shangle

Robert Brian Walsh

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-14

Filing date

2005-05-13

Publication date

2016-11-28

2005-05-13 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2016-11-28 Publication of HUE027757T2 publication Critical patent/HUE027757T2/en

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 19
201000010099 disease Diseases 0.000 title abstract description 18
238000011282 treatment Methods 0.000 title description 30
239000003242 anti bacterial agent Substances 0.000 title description 23
229940088710 antibiotic agent Drugs 0.000 title description 18
239000011230 binding agent Substances 0.000 claims description 2
239000000551 dentifrice Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 112
241000193163 Clostridioides difficile Species 0.000 abstract description 45
108010059993 Vancomycin Proteins 0.000 abstract description 33
229960003165 vancomycin Drugs 0.000 abstract description 33
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract description 33
239000008194 pharmaceutical composition Substances 0.000 abstract description 8
241000191967 Staphylococcus aureus Species 0.000 abstract description 6
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 abstract description 4
229960003085 meticillin Drugs 0.000 abstract description 4
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
230000003115 biocidal effect Effects 0.000 description 43
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 32
239000000203 mixture Substances 0.000 description 31
206010012735 Diarrhoea Diseases 0.000 description 23
239000010410 layer Substances 0.000 description 20
229960000282 metronidazole Drugs 0.000 description 20
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 20
230000000694 effects Effects 0.000 description 18
229920000642 polymer Polymers 0.000 description 18
238000009472 formulation Methods 0.000 description 16
-1 furán Chemical compound 0.000 description 14
210000001035 gastrointestinal tract Anatomy 0.000 description 14
239000003826 tablet Substances 0.000 description 14
206010009657 Clostridium difficile colitis Diseases 0.000 description 13
208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 13
208000015181 infectious disease Diseases 0.000 description 13
238000002560 therapeutic procedure Methods 0.000 description 13
229930187202 Tiacumicin Natural products 0.000 description 12
206010009887 colitis Diseases 0.000 description 12
241000894006 Bacteria Species 0.000 description 11
238000000576 coating method Methods 0.000 description 11
ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 11
229960000628 fidaxomicin Drugs 0.000 description 11
239000000546 pharmaceutical excipient Substances 0.000 description 11
206010037128 Pseudomembranous colitis Diseases 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 10
239000003814 drug Substances 0.000 description 10
239000004005 microsphere Substances 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
229940079593 drug Drugs 0.000 description 9
239000011248 coating agent Substances 0.000 description 8
238000000034 method Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000000126 substance Substances 0.000 description 8
241000282414 Homo sapiens Species 0.000 description 7
239000002775 capsule Substances 0.000 description 7
238000013270 controlled release Methods 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
238000002512 chemotherapy Methods 0.000 description 6
239000012729 immediate-release (IR) formulation Substances 0.000 description 6
241000894007 species Species 0.000 description 6
150000007549 18-membered macrocycles Chemical class 0.000 description 5
241000193403 Clostridium Species 0.000 description 5
229960002227 clindamycin Drugs 0.000 description 5
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 5
210000001072 colon Anatomy 0.000 description 5
239000002702 enteric coating Substances 0.000 description 5
238000009505 enteric coating Methods 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
230000002265 prevention Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
208000004998 Abdominal Pain Diseases 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
241000193468 Clostridium perfringens Species 0.000 description 4
241000186660 Lactobacillus Species 0.000 description 4
101710084578 Short neurotoxin 1 Proteins 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
101710182532 Toxin a Proteins 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000011247 coating layer Substances 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
208000010227 enterocolitis Diseases 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
229940039696 lactobacillus Drugs 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
244000052769 pathogen Species 0.000 description 4
239000000843 powder Substances 0.000 description 4
210000000813 small intestine Anatomy 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
231100000033 toxigenic Toxicity 0.000 description 4
230000001551 toxigenic effect Effects 0.000 description 4
239000003053 toxin Substances 0.000 description 4
231100000765 toxin Toxicity 0.000 description 4
108700012359 toxins Proteins 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
238000010268 HPLC based assay Methods 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
241000295644 Staphylococcaceae Species 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
238000001815 biotherapy Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000018044 dehydration Effects 0.000 description 3
238000006297 dehydration reaction Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
230000002550 fecal effect Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000011241 protective layer Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
108010001478 Bacitracin Proteins 0.000 description 2
RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 2
208000002881 Colic Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
241000194033 Enterococcus Species 0.000 description 2
241001495410 Enterococcus sp. Species 0.000 description 2
101710146739 Enterotoxin Proteins 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
206010057071 Rectal tenesmus Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241001147693 Staphylococcus sp. Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
101710182223 Toxin B Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
229960003071 bacitracin Drugs 0.000 description 2
229930184125 bacitracin Natural products 0.000 description 2
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
208000037815 bloodstream infection Diseases 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
239000004203 carnauba wax Substances 0.000 description 2
235000013869 carnauba wax Nutrition 0.000 description 2
229940082483 carnauba wax Drugs 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000013339 cereals Nutrition 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
235000009508 confectionery Nutrition 0.000 description 2
230000034994 death Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000000147 enterotoxin Substances 0.000 description 2
231100000655 enterotoxin Toxicity 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
229960004667 ethyl cellulose Drugs 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
229940014259 gelatin Drugs 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000011553 hamster model Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
229960002181 saccharomyces boulardii Drugs 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
231100000057 systemic toxicity Toxicity 0.000 description 2
208000012271 tenesmus Diseases 0.000 description 2
230000036962 time dependent Effects 0.000 description 2
229940031572 toxoid vaccine Drugs 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
HXBYBCASAVUYKF-GVYWOMJSSA-N (4r,5s,6r,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO HXBYBCASAVUYKF-GVYWOMJSSA-N 0.000 description 1
HXBYBCASAVUYKF-YTQLPXDHSA-N (4r,5s,6s,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO HXBYBCASAVUYKF-YTQLPXDHSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
208000020706 Autistic disease Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
241001112695 Clostridiales Species 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241000699679 Cricetulus migratorius Species 0.000 description 1
241001495431 Dactylosporangium aurantiacum Species 0.000 description 1
208000012239 Developmental disease Diseases 0.000 description 1
206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
241000191936 Micrococcus sp. Species 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
CJBIUUVHWWAIPX-ZCEGTHKRSA-N N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)-2-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxan-3-yl]acetamide Chemical compound C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)C1(O)[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@H](O1)CO CJBIUUVHWWAIPX-ZCEGTHKRSA-N 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
238000012565 NMR experiment Methods 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
241000193465 Paeniclostridium sordellii Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241000364057 Peoria Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
240000001717 Vaccinium macrocarpon Species 0.000 description 1
235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
241001148470 aerobic bacillus Species 0.000 description 1
238000002814 agar dilution Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
238000009635 antibiotic susceptibility testing Methods 0.000 description 1
235000015197 apple juice Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000003181 biological factor Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
239000007894 caplet Substances 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229940075419 choline hydroxide Drugs 0.000 description 1
208000019902 chronic diarrheal disease Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
235000004634 cranberry Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
201000007869 emphysematous cholecystitis Diseases 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000012055 enteric layer Substances 0.000 description 1
230000000688 enterotoxigenic effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical class FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
235000013376 functional food Nutrition 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229940059103 granules for oral solution Drugs 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
239000003906 humectant Substances 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
150000002678 macrocyclic compounds Chemical class 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
208000004840 megacolon Diseases 0.000 description 1
NXMXPVQZFYYPGD-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate Chemical compound COC(=O)C=C.COC(=O)C(C)=C NXMXPVQZFYYPGD-UHFFFAOYSA-N 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
230000000050 nutritive effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
238000000053 physical method Methods 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
150000003214 pyranose derivatives Chemical class 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
208000026773 severe abdominal cramp Diseases 0.000 description 1
208000026775 severe diarrhea Diseases 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
230000003997 social interaction Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
229940057977 zinc stearate Drugs 0.000 description 1
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Virology (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

HUE09156339A 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics HUE027757T2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US57069704P	2004-05-14	2004-05-14

Publications (1)

Publication Number	Publication Date
HUE027757T2 true HUE027757T2 (en)	2016-11-28

Family

ID=35428857

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
HUE09156339A HUE027757T2 (en)	2004-05-14	2005-05-13	Treatment of diseases associated with the use of antibiotics
HUE10075450A HUE043945T2 (hu)	2004-05-14	2005-05-13	Betegségek kezelése antibiotikumok használatával összefüggésben
HUE10075449A HUE031581T2 (en)	2004-05-14	2005-05-13	Treatment of diseases associated with the use of antibiotics

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
HUE10075450A HUE043945T2 (hu)	2004-05-14	2005-05-13	Betegségek kezelése antibiotikumok használatával összefüggésben
HUE10075449A HUE031581T2 (en)	2004-05-14	2005-05-13	Treatment of diseases associated with the use of antibiotics

Country Status (17)

Country	Link
US (2)	US20070173462A1 (de)
EP (4)	EP2305244B1 (de)
JP (2)	JP5734545B2 (de)
AT (1)	ATE516024T1 (de)
BR (1)	BRPI0511119A (de)
CA (2)	CA2776682A1 (de)
CY (2)	CY1117501T1 (de)
DK (3)	DK2305244T3 (de)
ES (4)	ES2395404T3 (de)
HU (3)	HUE027757T2 (de)
LT (1)	LT2305245T (de)
MX (2)	MX344601B (de)
PL (3)	PL2070530T3 (de)
PT (2)	PT2305244T (de)
SI (2)	SI2305245T1 (de)
TR (1)	TR201902533T4 (de)
WO (1)	WO2005112990A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006085838A1 (en) *	2005-01-31	2006-08-17	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US7906489B2 (en) *	2004-05-14	2011-03-15	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US8586551B2 (en)	2005-01-31	2013-11-19	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US7378508B2 (en)	2007-01-22	2008-05-27	Optimer Pharmaceuticals, Inc.	Polymorphic crystalline forms of tiacumicin B
CA2626698C (en) *	2005-10-21	2015-12-01	Optimer Pharmaceuticals, Inc.	Method of treating clostridium difficile-associated diarrhea
TWI523654B (zh) *	2007-11-27	2016-03-01	默沙東藥廠	抗生素巨環化合物以及其製造及使用之方法
US20110008303A1 (en) *	2008-03-17	2011-01-13	Cedars-Sinai Medical Center	Methods for treatment and prevention of mrsa/mssa
WO2011044208A1 (en) *	2009-10-06	2011-04-14	Scott Dorfner	Antibiotic formulations providing reduced gastrointentestinal side effects
AU2010320558A1 (en) *	2009-11-17	2012-07-12	Piramal Enterprises Limited	Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
MX348611B (es) *	2009-12-31	2017-06-21	Milton Trachtman Ira	Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
BR112012029259A8 (pt) *	2010-05-18	2021-03-23	Optimer Pharmaceuticals Inc	tratamento de infecção por clostridium difficile em pacientes sob terapia de antibióticos
JO3464B1 (ar)	2013-01-15	2020-07-05	Astellas Pharma Europe Ltd	التركيبات الخاصة بمركبات التياكوميسين
WO2015169451A1 (en)	2014-05-09	2015-11-12	Astellas Pharma Europe Ltd	Treatment regimen tiacumicin compound
MX2020005875A (es)	2017-12-05	2020-10-08	Bioplx Inc	Métodos y composiciones para prevenir la infección microbiana.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3279995A (en)	1963-05-31	1966-10-18	Allen F Reid	Shaped pellets
GB1458512A (en) *	1973-11-22	1976-12-15	Lepetit Spa	Antibiotic substance
US4111202A (en)	1976-11-22	1978-09-05	Alza Corporation	Osmotic system for the controlled and delivery of agent over time
US4918174A (en)	1986-09-26	1990-04-17	Abbott Laboratories	Tiacumicin compounds
US4786503A (en)	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
US5443841A (en)	1992-06-15	1995-08-22	Emisphere Technologies, Inc.	Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en)	1992-04-24	2001-05-22	Brown University Research Foundation	Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) *	1995-05-09	1996-12-10	Abbott Laboratories	Dialkyltiacumicin compounds
US6143211A (en)	1995-07-21	2000-11-07	Brown University Foundation	Process for preparing microparticles through phase inversion phenomena
US5767096A (en) *	1996-07-12	1998-06-16	Abbott Laboratories	Bromotiacumicin compounds
IN186245B (de)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
ES2327830T3 (es) *	2002-03-29	2009-11-04	Schering Corporation	Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US20070105791A1 (en) *	2002-07-29	2007-05-10	Optimer Pharmaceuticals, Inc.	Method of treating clostridium difficile-associated diarrhea
US7507564B2 (en) *	2002-07-29	2009-03-24	Optimer Pharmaceuticals, Inc.	Tiacumicin production
US7906489B2 (en) *	2004-05-14	2011-03-15	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US7378508B2 (en) *	2007-01-22	2008-05-27	Optimer Pharmaceuticals, Inc.	Polymorphic crystalline forms of tiacumicin B
US8586551B2 (en) *	2005-01-31	2013-11-19	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
ZA200905337B (en) *	2007-01-22	2010-10-27	Optimer Pharmaceuticals Inc	Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) *	2007-11-27	2016-03-01	默沙東藥廠	抗生素巨環化合物以及其製造及使用之方法

2005
- 2005-05-13 ES ES05748007T patent/ES2395404T3/es not_active Expired - Lifetime
- 2005-05-13 PL PL09156339T patent/PL2070530T3/pl unknown
- 2005-05-13 SI SI200532245T patent/SI2305245T1/sl unknown
- 2005-05-13 HU HUE09156339A patent/HUE027757T2/en unknown
- 2005-05-13 US US11/596,340 patent/US20070173462A1/en not_active Abandoned
- 2005-05-13 BR BRPI0511119-6A patent/BRPI0511119A/pt not_active IP Right Cessation
- 2005-05-13 DK DK10075449.8T patent/DK2305244T3/en active
- 2005-05-13 CA CA2776682A patent/CA2776682A1/en not_active Withdrawn
- 2005-05-13 TR TR2019/02533T patent/TR201902533T4/tr unknown
- 2005-05-13 HU HUE10075450A patent/HUE043945T2/hu unknown
- 2005-05-13 ES ES10075450T patent/ES2713954T3/es not_active Expired - Lifetime
- 2005-05-13 PL PL10075449T patent/PL2305244T3/pl unknown
- 2005-05-13 ES ES10075449.8T patent/ES2608046T3/es not_active Expired - Lifetime
- 2005-05-13 HU HUE10075449A patent/HUE031581T2/en unknown
- 2005-05-13 DK DK09156339.5T patent/DK2070530T3/da active
- 2005-05-13 EP EP10075449.8A patent/EP2305244B1/de not_active Expired - Lifetime
- 2005-05-13 WO PCT/US2005/016750 patent/WO2005112990A2/en not_active Ceased
- 2005-05-13 EP EP05748007A patent/EP1765312B1/de not_active Expired - Lifetime
- 2005-05-13 MX MX2014003990A patent/MX344601B/es unknown
- 2005-05-13 MX MXPA06013245A patent/MXPA06013245A/es active IP Right Grant
- 2005-05-13 AT AT05748007T patent/ATE516024T1/de not_active IP Right Cessation
- 2005-05-13 DK DK10075450.6T patent/DK2305245T3/en active
- 2005-05-13 PT PT100754498T patent/PT2305244T/pt unknown
- 2005-05-13 ES ES09156339.5T patent/ES2565609T3/es not_active Expired - Lifetime
- 2005-05-13 JP JP2007513392A patent/JP5734545B2/ja not_active Expired - Lifetime
- 2005-05-13 EP EP10075450.6A patent/EP2305245B1/de not_active Expired - Lifetime
- 2005-05-13 LT LTEP10075450.6T patent/LT2305245T/lt unknown
- 2005-05-13 PT PT10075450T patent/PT2305245T/pt unknown
- 2005-05-13 EP EP09156339.5A patent/EP2070530B1/de not_active Expired - Lifetime
- 2005-05-13 CA CA2566687A patent/CA2566687C/en not_active Expired - Lifetime
- 2005-05-13 PL PL10075450T patent/PL2305245T3/pl unknown
- 2005-05-13 SI SI200532054A patent/SI2070530T1/sl unknown
2012
- 2012-04-26 US US13/457,216 patent/US20130274175A1/en not_active Abandoned
- 2012-06-19 JP JP2012138170A patent/JP6101010B2/ja not_active Expired - Lifetime
2016
- 2016-05-13 CY CY20161100404T patent/CY1117501T1/el unknown
2019
- 2019-02-28 CY CY20191100248T patent/CY1121284T1/el unknown

Also Published As

Publication number	Publication date
JP2007537290A (ja)	2007-12-20
PL2305244T3 (pl)	2017-04-28
SI2305245T1 (sl)	2019-04-30
PT2305245T (pt)	2019-03-19
CY1121284T1 (el)	2020-05-29
EP1765312A4 (de)	2007-08-22
US20130274175A1 (en)	2013-10-17
US20070173462A1 (en)	2007-07-26
ES2608046T3 (es)	2017-04-05
TR201902533T4 (tr)	2019-03-21
PT2305244T (pt)	2016-12-29
HUE043945T2 (hu)	2019-09-30
PL2070530T3 (pl)	2016-06-30
DK2305244T3 (en)	2017-01-30
CY1117501T1 (el)	2017-04-26
EP2305245B1 (de)	2019-01-02
ATE516024T1 (de)	2011-07-15
EP1765312A2 (de)	2007-03-28
LT2305245T (lt)	2019-03-12
JP6101010B2 (ja)	2017-03-22
EP2070530A1 (de)	2009-06-17
JP2012197309A (ja)	2012-10-18
MX344601B (es)	2016-12-20
CA2566687C (en)	2012-07-24
EP2070530B1 (de)	2016-02-17
ES2565609T3 (es)	2016-04-05
SI2070530T1 (sl)	2016-05-31
DK2305245T3 (en)	2019-03-25
EP2305245A1 (de)	2011-04-06
WO2005112990A3 (en)	2006-01-05
MXPA06013245A (es)	2007-05-09
WO2005112990A2 (en)	2005-12-01
CA2776682A1 (en)	2005-12-01
CA2566687A1 (en)	2005-12-01
HUE031581T2 (en)	2017-07-28
EP2305244B1 (de)	2016-10-12
JP5734545B2 (ja)	2015-06-17
ES2713954T3 (es)	2019-05-24
PL2305245T3 (pl)	2019-05-31
EP1765312B1 (de)	2011-07-13
EP2305244A1 (de)	2011-04-06
DK2070530T3 (da)	2016-05-17
ES2395404T3 (es)	2013-02-12
BRPI0511119A (pt)	2007-11-27

Publication	Publication Date	Title
JP6101010B2 (ja)	2017-03-22	抗生物質の使用に関連する疾患の治療
EP2222309B1 (de)	2015-10-28	Antibiotische makrocyclische verbindungen und herstellungs- und anwendungsverfahren
AU2005327308B2 (en)	2011-11-10	18-membered macrocycles and analogs thereof
US7906489B2 (en)	2011-03-15	18-membered macrocycles and analogs thereof
US8586551B2 (en)	2013-11-19	18-membered macrocycles and analogs thereof
JP5825217B2 (ja)	2015-12-02	１８員大環状化合物及びその類似化合物
HK1155983A (en)	2012-06-01	Treatment of diseases associated with the use of antibiotics
HK1155947A (en)	2012-06-01	Treatment of diseases associated with the use of antibiotics
AU2013245517B2 (en)	2016-05-26	18-membered macrocycles and analogs thereof
HK1174260A (en)	2013-06-07	18-membered macrocycles and analogs thereof